These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

290 related articles for article (PubMed ID: 29341831)

  • 41. Clinical Practice Guideline: Sudden Hearing Loss (Update).
    Chandrasekhar SS; Tsai Do BS; Schwartz SR; Bontempo LJ; Faucett EA; Finestone SA; Hollingsworth DB; Kelley DM; Kmucha ST; Moonis G; Poling GL; Roberts JK; Stachler RJ; Zeitler DM; Corrigan MD; Nnacheta LC; Satterfield L
    Otolaryngol Head Neck Surg; 2019 Aug; 161(1_suppl):S1-S45. PubMed ID: 31369359
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Clinical Practice Guideline: Sudden Hearing Loss (Update) Executive Summary.
    Chandrasekhar SS; Tsai Do BS; Schwartz SR; Bontempo LJ; Faucett EA; Finestone SA; Hollingsworth DB; Kelley DM; Kmucha ST; Moonis G; Poling GL; Roberts JK; Stachler RJ; Zeitler DM; Corrigan MD; Nnacheta LC; Satterfield L; Monjur TM
    Otolaryngol Head Neck Surg; 2019 Aug; 161(2):195-210. PubMed ID: 31369349
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Delaying skeletal-related events in a randomized phase 3 study of denosumab versus zoledronic acid in patients with advanced cancer: an analysis of data from patients with solid tumors.
    Henry D; Vadhan-Raj S; Hirsh V; von Moos R; Hungria V; Costa L; Woll PJ; Scagliotti G; Smith G; Feng A; Jun S; Dansey R; Yeh H
    Support Care Cancer; 2014 Mar; 22(3):679-87. PubMed ID: 24162260
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Bone disease in myeloma.
    Berenson JR
    Curr Treat Options Oncol; 2001 Jun; 2(3):271-83. PubMed ID: 12057127
    [TBL] [Abstract][Full Text] [Related]  

  • 45. American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer.
    Hillner BE; Ingle JN; Chlebowski RT; Gralow J; Yee GC; Janjan NA; Cauley JA; Blumenstein BA; Albain KS; Lipton A; Brown S;
    J Clin Oncol; 2003 Nov; 21(21):4042-57. PubMed ID: 12963702
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial.
    Rosen LS; Gordon D; Kaminski M; Howell A; Belch A; Mackey J; Apffelstaedt J; Hussein MA; Coleman RE; Reitsma DJ; Chen BL; Seaman JJ
    Cancer; 2003 Oct; 98(8):1735-44. PubMed ID: 14534891
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A cost-effectiveness analysis of denosumab for the prevention of skeletal-related events in patients with multiple myeloma in the United States of America.
    Raje N; Roodman GD; Willenbacher W; Shimizu K; García-Sanz R; Terpos E; Kennedy L; Sabatelli L; Intorcia M; Hechmati G
    J Med Econ; 2018 May; 21(5):525-536. PubMed ID: 29480139
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Renal safety of 1-hour pamidronate infusion for breast cancer and multiple myeloma patients: comparison between clinical trials and population-based database.
    de Lemos ML; Taylor SC; Barnett JB; Hu F; Levin A; Moravan V; O'Reilly SE
    J Oncol Pharm Pract; 2006 Dec; 12(4):193-9. PubMed ID: 17156591
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Bone modifying agents for patients with bone metastases from breast cancer managed in routine practice setting: Treatment patterns and outcome.
    Zekri J; Farag K; Yousof O; Zabani Y; Mohamed W; Ahmed GA
    J Oncol Pharm Pract; 2020 Jun; 26(4):906-911. PubMed ID: 31575357
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Zoledronic acid reduces skeletal-related events in patients with osteolytic metastases.
    Berenson JR; Rosen LS; Howell A; Porter L; Coleman RE; Morley W; Dreicer R; Kuross SA; Lipton A; Seaman JJ
    Cancer; 2001 Apr; 91(7):1191-200. PubMed ID: 11283917
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Risk factors for renal impairment in patients with solid tumors or multiple myeloma treated with zoledronic acid.
    Cha YJ; Lee YJ
    Int J Clin Pharmacol Ther; 2013 Apr; 51(4):274-82. PubMed ID: 23357846
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Continued Treatment Effect of Zoledronic Acid Dosing Every 12 vs 4 Weeks in Women With Breast Cancer Metastatic to Bone: The OPTIMIZE-2 Randomized Clinical Trial.
    Hortobagyi GN; Van Poznak C; Harker WG; Gradishar WJ; Chew H; Dakhil SR; Haley BB; Sauter N; Mohanlal R; Zheng M; Lipton A
    JAMA Oncol; 2017 Jul; 3(7):906-912. PubMed ID: 28125763
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Role of Bone-Modifying Agents in Metastatic Breast Cancer: An American Society of Clinical Oncology-Cancer Care Ontario Focused Guideline Update Summary.
    Van Poznak C; Somerfield MR; Moy B
    J Oncol Pract; 2017 Dec; 13(12):822-824. PubMed ID: 29035617
    [No Abstract]   [Full Text] [Related]  

  • 54. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study.
    Stopeck AT; Lipton A; Body JJ; Steger GG; Tonkin K; de Boer RH; Lichinitser M; Fujiwara Y; Yardley DA; Viniegra M; Fan M; Jiang Q; Dansey R; Jun S; Braun A
    J Clin Oncol; 2010 Dec; 28(35):5132-9. PubMed ID: 21060033
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A comprehensive review of denosumab for bone metastasis in patients with solid tumors.
    Gül G; Sendur MA; Aksoy S; Sever AR; Altundag K
    Curr Med Res Opin; 2016; 32(1):133-45. PubMed ID: 26451465
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Clinical Practice Guideline: Tonsillectomy in Children (Update)-Executive Summary.
    Mitchell RB; Archer SM; Ishman SL; Rosenfeld RM; Coles S; Finestone SA; Friedman NR; Giordano T; Hildrew DM; Kim TW; Lloyd RM; Parikh SR; Shulman ST; Walner DL; Walsh SA; Nnacheta LC
    Otolaryngol Head Neck Surg; 2019 Feb; 160(2):187-205. PubMed ID: 30921525
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study.
    Fizazi K; Carducci M; Smith M; Damião R; Brown J; Karsh L; Milecki P; Shore N; Rader M; Wang H; Jiang Q; Tadros S; Dansey R; Goessl C
    Lancet; 2011 Mar; 377(9768):813-22. PubMed ID: 21353695
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Use of Bone-Modifying Agents in Myeloma and Bone Metastases: How Recent Dosing Interval Studies Have Affected Our Practice.
    Campagnaro E; Reimers MA; Qin A; Alva AS; Schneider BJ; Van Poznak CH
    J Oncol Pract; 2018 Aug; 14(8):457-464. PubMed ID: 30096277
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Platelet Transfusion for Patients With Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update.
    Schiffer CA; Bohlke K; Delaney M; Hume H; Magdalinski AJ; McCullough JJ; Omel JL; Rainey JM; Rebulla P; Rowley SD; Troner MB; Anderson KC
    J Clin Oncol; 2018 Jan; 36(3):283-299. PubMed ID: 29182495
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A Phase IB multicentre dose-determination study of BHQ880 in combination with anti-myeloma therapy and zoledronic acid in patients with relapsed or refractory multiple myeloma and prior skeletal-related events.
    Iyer SP; Beck JT; Stewart AK; Shah J; Kelly KR; Isaacs R; Bilic S; Sen S; Munshi NC
    Br J Haematol; 2014 Nov; 167(3):366-75. PubMed ID: 25139740
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.